文献速递心力衰竭与心肌病瓣膜病与结构性心脏病心律失常

经皮心肌内室间隔射频消融术治疗药物难治性非梗阻性肥厚型心肌病

Percutaneous intramyocardial septal radiofrequency ablation: a novel treatment for drug-refractory non-obstructive hypertrophic cardiomyopathy with severe septal hypertrophy.
PubMed 文献 · Heart · 2025-09-11

本研究为单臂、开放标签、前瞻性研究,纳入20例药物难治性非梗阻性肥厚型心肌病(NOHCM)且室间隔重度肥厚(≥28 mm)的成人患者,行经皮心肌内室间隔射频消融术(PIMSRA,Liwen术),中位随访15个月。结果显示室间隔厚度显著下降,生活质量与心肌功能改善,30天内无主要不良临床事件。

要点

  • PIMSRA可显著降低NOHCM患者的最大室间隔厚度。
  • 术后KCCQ-12评分及心肌应变指标改善。
  • 30天内无主要不良临床事件,随访未见心律失常风险增加。

核心结论

  • PIMSRA与NOHCM患者室间隔厚度降低及功能状态改善相关。
  • 术后未发生主要不良事件,但需更大样本对照研究确认长期安全性。

研究设计与样本

  • 单臂、开放标签、前瞻性研究,纳入20例药物难治性NOHCM且室间隔厚度≥28 mm的成人患者。
  • 患者接受PIMSRA治疗,中位随访15个月。

主要发现

  • 最大室间隔厚度从31.3 mm降至17.4 mm(平均差-13.9 mm;95%CI -15.92至-11.88)。
  • 左房容积指数和左心室质量指数亦显著下降。
  • 整体纵向应变和整体径向应变改善,提示心肌性能可能增强。
  • KCCQ-12评分从65.6升至84.4(平均差18.78;95%CI 11.62至25.93)。
  • 随访期间未发现房颤、高级别传导阻滞或非持续性室速等心律失常风险增加。

临床怎么用

  • 对于药物难治性NOHCM且室间隔重度肥厚的患者,PIMSRA可作为潜在介入选择。
  • 术后需随访室间隔厚度、心功能及心律失常事件。

局限性

  • 单臂研究,无对照组,样本量小(20例),随访时间有限。
  • 长期安全性和有效性需更大规模对照研究证实。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with drug-refractory non-obstructive hypertrophic cardiomyopathy (NOHCM) lack effective invasive treatment options. This study aimed to evaluate the safety and effectiveness of percutaneous intramyocardial septal radiofrequency ablation (PIMSRA, Liwen procedure) in patients with NOHCM and severe septal hypertrophy (≥28 mm). METHOD: This single-arm, open-label, prospective study enrolled 20 adult patients with drug-refractory NOHCM between June 2017 and June 2023. Patients underwent PIMSRA and were followed for a median of 15 months. Outcomes included changes in septal thickness, quality of life (Kansas City Cardiomyopathy Questionnaire-12, KCCQ-12) and myocardial function. RESULTS: No major adverse clinical events occurred within 30 days after the procedure. The maximum interventricular septal thickness decreased significantly from 31.3 mm to 17.4 mm (mean difference: -13.9 mm; 95% CI -15.92 to -11.88). Left atrial volume index and left ventricular mass index also decreased significantly. Improvements in global longitudinal strain and global radial strain were observed, indicating possibly enhanced myocardial performance. KCCQ-12 scores improved from 65.6 to 84.4 (mean difference: 18.78; 95% CI 11.62 to 25.93). Patients after PIMSRA were not found to have an increased risk of arrhythmias such as atrial fibrillation, high-grade conduction block or non-sustained ventricular tachycardia during the follow-up. CONCLUSIONS: PIMSRA was associated with a reduction of myocardial septal thickness and improvement in functional status in patients with NOHCM. The absence of major adverse events is also encouraging, but larger studies with a control arm are needed to confirm long-term safety. TRIAL REGISTRATION NUMBER: ChiCTR1900020530.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. Wang H, Li J, Hsi DH, et al. Percutaneous intramyocardial septal radiofrequency ablation: a novel treatment for drug-refractory non-obstructive hypertrophic cardiomyopathy with severe septal hypertrophy. Heart. 2025. PMID: 40054888. doi:10.1136/heartjnl-2024-325334

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。